南新制药(688189) - 2025 Q4 - 年度业绩

Financial Performance - Total revenue for 2025 was CNY 141.93 million, a decrease of 46.09% compared to the previous year[4] - Operating profit for 2025 was CNY -132.51 million, with a total profit of CNY -132.67 million[4] - Net profit attributable to shareholders was CNY -137.25 million, a significant decline from CNY -356.90 million in the previous year[4] - Basic earnings per share for 2025 was CNY -0.5006, improving from CNY -1.3007 year-on-year[4] Assets and Equity - Total assets at the end of 2025 were CNY 809.54 million, down 33.78% from the previous year[6] - Shareholders' equity attributable to the parent company decreased to CNY 783.20 million, a reduction of 16.38%[6] Return on Investment - The weighted average return on net assets improved by 16.03 percentage points to -15.84%[4] Market Conditions - The company faced intensified market competition due to domestic pharmaceutical procurement policies and the introduction of similar products[7] Research and Development - The company maintained high R&D investment to sustain core competitiveness despite the losses[7] Financial Management - The company successfully reduced interest-bearing liabilities and accounts payable, leading to a lower asset-liability ratio[9]